Johnson & Johnson (NYSE:JNJ) Shares Bought by Rep. Lloyd Doggett

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on October 5th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on September 8th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 9/11/2026.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 9/10/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/17/2026.

Johnson & Johnson Trading Up 0.8%

NYSE:JNJ opened at $254.85 on Wednesday. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07. The firm has a 50-day moving average price of $265.86 and a two-hundred day moving average price of $248.63. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $614.17 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JNJ shares. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research report on Wednesday, July 15th. Wells Fargo & Company raised their target price on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $276.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Innovative Medicines is offsetting MedTech pressure. RBC Capital Markets said accelerating momentum in J&J’s Innovative Medicines business is helping counter persistent headwinds in MedTech. New drug launches and portfolio diversification remain key reasons analysts see support for the shares. Johnson & Johnson’s Innovative Medicines Momentum Offsets MedTech Headwinds
• Positive Sentiment: Defensive dividend characteristics are attracting investors. Analysts continue to highlight J&J’s diversified healthcare portfolio, recurring demand and dividend reliability as advantages during an economic downturn. Those qualities may support the stock’s valuation and limit downside volatility. Looking for a Dividend Stock That Can Weather a Downturn?
• Positive Sentiment: MedTech could improve later in the year. While Abiomed and broader competitive pressures weighed on the segment, Vision, Orthopedics and Surgery may produce a stronger second half and help restore growth. Can J&J’s MedTech Business Rebound in Q3 After Q2 Slowdown?
• Neutral Sentiment: Investors are focused on the October 13 earnings report. Recent commentary questions whether J&J has the setup for another earnings beat, making upcoming results and management’s guidance important near-term catalysts. The company previously exceeded EPS and revenue expectations and forecast fiscal 2026 EPS of $11.60–$11.75.
• Negative Sentiment: The 2027 patent cliff remains the main overhang. Articles warn that roughly $4 billion of revenue may be exposed when key patents expire in 2027. Investors are therefore evaluating whether J&J’s drug pipeline and replacement launches can offset the loss, rather than focusing only on the next quarter’s EPS. The Next Patent Cliff Will Test a Replacement Engine
• Neutral Sentiment: Management is emphasizing artificial intelligence. CEO Joaquin Duato described AI as a force multiplier that J&J needs to embrace, but the interview offered limited near-term financial detail. Johnson & Johnson CEO Says AI Has to Be Embraced

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Auto Owners Insurance Co lifted its holdings in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Wellington Management Group LLP raised its position in Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after purchasing an additional 1,376,828 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Finally, Amundi increased its position in shares of Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.